The effect of antithrombotic therapy on the recurrence and outcome of chronic subdural hematoma after burr-hole craniostomy in a population-based cohort - Takeaways - MDSpire

The effect of antithrombotic therapy on the recurrence and outcome of chronic subdural hematoma after burr-hole craniostomy in a population-based cohort

  • By

  • Santtu Kerttula

  • Jukka Huttunen

  • Ville Leinonen

  • Olli-Pekka Kämäräinen

  • Nils Danner

  • August 16, 2022

  • 0 min

Share

  • 1

    Chronic subdural hematoma (CSDH) has an incidence of up to 129.5/100,000 in individuals aged 80 years and older.

  • 2

    Antithrombotic therapy (ATT) is a common risk factor for CSDH, alongside age, male gender, and alcohol abuse.

  • 3

    In a study of 301 patients, ATT did not significantly affect the recurrence of CSDH after burr-hole craniostomy.

  • 4

    The overall 3-year mortality rate among the study cohort was 27.9%, with 15.8% experiencing hematoma recurrence.

  • 5

    The mean time to reoperation for hematoma recurrence was shorter in patients on ATT, but the difference was not statistically significant.

Original Source(s)

The effect of antithrombotic therapy on the recurrence and outcome of chronic subdural hematoma after burr-hole craniostomy in a population-based cohort

  • by Santtu Kerttula, Jukka Huttunen, Ville Leinonen, Olli-Pekka Kämäräinen, Nils Danner

  • August 16, 2022

Related Content

Augmented reality and 3D visualization integrated with magnetic-assisted robotic procedures: first clinical cases using combined cutting-edge technologies

Collaborative Team Strategies in Surgical Management of Placenta Accreta: Issues and Insights

AAE Revises Dental Trauma Guidance

Recommendations outline splinting, replantation timing, imaging, and long-term surveillance strategies for permanent tooth injuries.